New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
08:47 EDTEPZMEpizyme price target raised to $52 from $37 at Wedbush
Wedbush increased its price target on Epizyme after the company released clinical data on its EPZ-5676 treatment that the firm views as positive. The firm reiterates an Outperform rating on the stock.
News For EPZM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 18, 2015
06:03 EDTEPZMEpizyme 6M share Secondary priced at $20.75
Subscribe for More Information
March 16, 2015
16:05 EDTEPZMEpizyme files to sell 4.75M shares of common stock
Subscribe for More Information
March 12, 2015
07:13 EDTEPZMEpizyme reports Q4 EPS (44c), consensus (53c)
Reports Q4 revenue $10.3M, consensus $10.08M. CFO Andrew Singer said, “Epizyme has made significant strides in advancing as an independent oncology company. We began 2014 with $123.6M in cash and cash equivalents and ended the year with $190.1M in cash and cash equivalents, which reflects the proceeds from our public offering in 2014 and collaborator non-equity funding. As we move forward, we will continue to evaluate our operating plan to ensure that we are carefully monitoring our spend and providing for appropriate capital to be devoted to the aggressive development of EPZ-6438.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use